# Liposomal Bortezomib Nanoparticles via Boronic Ester Prodrug Formulation for Improved Therapeutic Efficacy *In Vivo*

Jonathan D. Ashley[1], Jared F. Stefanick[1], Valerie A. Shroeder[2,3], Mark A. Suckow[2,3], Tanyel Kiziltepe[1, 3†], Basar Bilgicer[1, 3, 4*]

[1]Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN 46556.

[2]Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556.

[3]Freimann Life Science Center, University of Notre Dame, Notre Dame, IN 46556.

[4]Advanced Diagnostics and Therapeutics, University of Notre Dame, Notre Dame, IN 46556.

[5]Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556.

[*]Email: *bbilgicer@nd.edu, tkiziltepe@nd.edu*

# Supplementary Information

## Table of Contents

Supplementary Figure S1……S-2

Supplementary Figure S2……S-3




**Supplementary Figure S1. Chemical shift of the boron peak in $^{11}$B-NMR.** Representative $^{11}$B-NMR spectra of the boron atom in IBBA as a boronic acid (32 ppm; blue) and a boronic ester (12 ppm; red).




**Supplementary Figure S2. Post-insertion efficiency of the prodrug conjugates.** Representative HPLC chromatograms of the liposomal bortezomib nanoparticles (red) and the theoretical loading maximum (blue).